Know Cancer

or
forgot password

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD


N/A
18 Years
N/A
Open (Enrolling)
Both
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera

Thank you

Trial Information

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD


Inclusion Criteria:



- Patients are to be registered to this study if they meet the eligibility criteria for
one of the MPD-RC treatment protocols linked to this study.

- Patients diagnosed with the following Myeloproliferative disorders including:
polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia
(ET) who are participating in treatment protocols of the MPD-RC are eligible.

- Patients must have signed an informed consent to participate in a Myeloproliferative
Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a
companion study. The subject must also have signed a consent to participate in this
mandatory companion study.

Exclusion Criteria:

See inclusion criteria.

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

To collect and store tissue samples from patients with myeloproliferative disorders (PV,IM,and ET). Tissue samples will be used to perform a variety of biomarker studies to monitor the effects of a particular therapeutic intervention.

Outcome Time Frame:

4 years

Safety Issue:

No

Principal Investigator

Rona S Weinberg, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Myeloproliferative Disorders-Research Consortium

Authority:

United States: Institutional Review Board

Study ID:

GCO 07-0548-00107

NCT ID:

NCT00665067

Start Date:

April 2007

Completion Date:

December 2015

Related Keywords:

  • Myeloproliferative Disease
  • Myelofibrosis
  • Idiopathic Myelofibrosis
  • Essential Thrombocythemia
  • Polycythemia Vera
  • Myeloproliferative Disease
  • Myelofibrosis
  • Idiopathic Myelofibrosis
  • Essential Thrombocythemia
  • Polycythemia Vera
  • Biomarkers
  • Philadelphia Chromosome Negative
  • Clonal Hematopoietic malignancies
  • Primary Myelofibrosis
  • Myeloproliferative Disorders
  • Philadelphia Chromosome
  • Polycythemia
  • Polycythemia Vera
  • Thrombocythemia, Essential
  • Thrombocytosis

Name

Location

University of Illinois at ChicagoChicago, Illinois  60612
New York Blood CenterNew York, New York  10021
University of UtahSalt Lake City, Utah  
University of PennsylvaniaPhiladelphia, Pennsylvania  19104
Georgetown UniversityWashington, District of Columbia  20007-2197
Ohio State UniversityColumbus, Ohio  43210
University of MarylandBaltimore, Maryland  21201
Mayo ClinicScottsdale, Arizona  
Johns Hopkins Medical CenterBaltimore, Maryland  
Wake Forest University Baptist Medical CenterWinston-Salem, North Carolina  27157
Weill Cornell Medical CollegeNew York, New York  10021
Emory HospitalAtlanta, Georgia  30322
The Palo Alto ClinicPalo Alto, California  94301
Geisinger Cancer CenterHazelton, Pennsylvania  18201
Icahn School of Medicine at Mount SinaiNew York, New York  10029